There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Xencor (XNCR – Research Report) and Neurogene (NGNE – Research Report) with bullish sentiments.
Xencor (XNCR)
In a report released yesterday, Tara Bancroft from TD Cowen maintained a Buy rating on Xencor. The company’s shares closed last Friday at $22.48.
According to TipRanks.com, Bancroft is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Xencor with a $35.89 average price target, implying a 52.1% upside from current levels. In a report issued on May 9, RBC Capital also maintained a Buy rating on the stock with a $32.00 price target.
See the top stocks recommended by analysts >>
Neurogene (NGNE)
In a report released yesterday, Ritu Baral from TD Cowen maintained a Buy rating on Neurogene. The company’s shares closed last Friday at $32.50.
According to TipRanks.com, Baral is a 4-star analyst with an average return of
Neurogene has an analyst consensus of Strong Buy, with a price target consensus of $48.33, which is a 44.7% upside from current levels. In a report issued on April 29, Leerink Partners also initiated coverage with a Buy rating on the stock with a $46.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on XNCR:
